Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAPID COVID COAG: Therapeutic Enoxaparin vs Standard Care in Hospitalized COVID-19 Patients
2020-002190-10Phase 3Completed
- Sponsor
- University College Dublin
- Start
- Jan 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of enoxaparin in coronavirus disease 2019 (COVID-19) and coagulopathy (2 arms), sponsored by University College Dublin. Primary endpoint: Primary composite outcome. Started Jan 2021; status: completed.
02
Drugs
enoxaparin
03
Conditions
coronavirus disease 2019 (COVID-19)coagulopathy
Beyond the preview
Go deeper on 2020-002190-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002190-10.